Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLand & ImprovementsLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pediatrix Medical (MD) Shares Outstanding (2016 - 2025)

Pediatrix Medical (MD) has disclosed Shares Outstanding for 17 consecutive years, with $83.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Shares Outstanding fell 3.37% to $83.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $83.0 million, a 3.37% decrease, with the full-year FY2025 number at $83.0 million, down 3.37% from a year prior.
  • Shares Outstanding was $83.0 million for Q4 2025 at Pediatrix Medical, down from $85.8 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $87.2 million in Q1 2022 to a low of $82.9 million in Q4 2022.
  • A 5-year average of $85.0 million and a median of $85.8 million in 2024 define the central range for Shares Outstanding.
  • Peak YoY movement for Shares Outstanding: fell 4.07% in 2023, then rose 2.31% in 2024.
  • Pediatrix Medical's Shares Outstanding stood at $86.4 million in 2021, then decreased by 4.02% to $82.9 million in 2022, then increased by 1.29% to $84.0 million in 2023, then grew by 2.2% to $85.9 million in 2024, then decreased by 3.37% to $83.0 million in 2025.
  • Per Business Quant, the three most recent readings for MD's Shares Outstanding are $83.0 million (Q4 2025), $85.8 million (Q3 2025), and $86.9 million (Q2 2025).